SGLT-2Is and dipeptidyl peptidase-4 inhibitors (DPP-4Is) do not cause hypoglycemia, are administered orally (The Royal Australian College of General Practitioners (RACGP), 2016), and may be preferred over sulfonylureas and insulin in people at high risk of hypoglycemia such as those who are frail (Ibrahim et al., 2020). This evidence concerns the gene DPP4 and Hypoglycemia.